Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Oct 4, 2025
Transactions
163
Purchases
0
Sales
163
Purchase value
$0.00
Sale value
$6.44M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Evnin LukeDirector
4Rule 10b5-1 plan disclosed
Filed Jul 8, 2026Period of report Jul 6, 20260001134657-26-000020
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 7, 2026
Common StockF1F6F7F4F8
107,429
$0.31
$33.30K
0
IndirectSee Footnotes
SaleJul 6, 2026
Common StockF1F2
Filing footnotes · 8
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F2The shares were sold as follows: 3,832 by MPM Asset Management LLC ("AM LLC"), 24,197 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,614 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 833 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,294 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3128 to $0.3388 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 11,509 by AM LLC, 72,676 by BV 2014, 4,845 by BV 2014(B), 2,499 by AM BV2014 and 15,900 by MPM OIF.
F6The shares were sold as follows: 11,509 by AM LLC, 72,676 by BV 2014, 4,845 by BV 2014(B), 2,499 by AM BV2014 and 15,900 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.295 to $0.3342 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8No shares held by AM LLC, BV 2014, BV 2014(B), AM BV2014 and MPM OIF.
Filed Nov 3, 2025Period of report Oct 30, 20250001231919-25-000406
Transaction
Security
Shares
Price
ValueValue (shares × price)
Gadicke Ansbert10% owner
MPM Asset Management LLC10% owner
MPM BioImpact LLC10% owner
MPM Oncology Innovations Fund GP LLC10% owner
MPM Oncology Innovations Fund LP10% owner
Oncology Impact Fund (Cayman) Management L.P.10% owner
UBS Oncology Impact Fund L.P.10% owner
4Rule 10b5-1 plan disclosed
Filed Nov 3, 2025Period of report Oct 30, 20250001231919-25-000404
Evnin LukeDirector
4Rule 10b5-1 plan disclosed
Filed Nov 3, 2025Period of report Oct 30, 20250001134657-25-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.
F3
F4
F5
35,770
$0.32
$11.45K
107,429
IndirectSee Footnotes
Jun 29, 2026
Common StockF1F2F3F4F5
157,084
$0.30
$47.13K
143,199
IndirectSee Footnotes
Filing footnotes · 5
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F2The shares were sold as follows: 16,830 by MPM Asset Management LLC ("AM LLC"), 106,262 by MPM BioVentures 2014, L.P. ("BV 2014"), 7,087 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 3,657 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 23,248 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2703 to $0.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 15,341 by AM LLC, 96,873 by BV 2014, 6,459 by BV 2014(B), 3,332 by AM BV2014 and 21,194 by MPM OIF.
F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3814 to $0.4129 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
F4Held directly by Nexus Fund II.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3757 to $0.3955 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3584 to $0.3906 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.36 to $0.3791 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
F4Held directly by Nexus Fund II.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3627 to $0.3791 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3945 to $0.3636 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F2The shares were sold as follows: 8,242 by MPM Asset Management LLC ("AM LLC"), 52,039 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,471 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,791 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,385 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3553 to $0.3851 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 32,171 by AM LLC, 203,135 by BV 2014, 13,546 by BV 2014(B), 6,989 by AM BV2014 and 44,442 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3706 to $0.4126 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 40,413 by AM LLC, 255,174 by BV 2014, 17,017 by BV 2014(B), 8,780 by AM BV2014 and 55,827 by MPM OIF.
F2The shares were sold as follows: 2,150 by MPM Asset Management LLC ("AM LLC"), 13,578 by MPM BioVentures 2014, L.P. ("BV 2014"), 906 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 467 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,971 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.4499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 49,573 by AM LLC, 313,005 by BV 2014, 20,875 by BV 2014(B), 10,771 by AM BV2014 and 68,480 by MPM OIF.
F6The shares were sold as follows: 2,673 by AM LLC, 16,874 by BV 2014, 1,126 by BV 2014(B), 581 by AM BV2014 and 3,692 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3918 to $0.454 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 46,900 by AM LLC, 296,131 by BV 2014, 19,749 by BV 2014(B), 10,190 by AM BV2014 and 64,788 by MPM OIF.
F9The shares were sold as follows: 6,487 by AM LLC, 40,957 by BV 2014, 2,732 by BV 2014(B), 1,410 by AM BV2014 and 8,961 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.42 to $0.4367 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 51,723 by AM LLC, 326,583 by BV 2014, 21,781 by BV 2014(B), 11,238 by AM BV2014 and 71,451 by MPM OIF.
F2The shares were sold as follows: 8,620 by MPM Asset Management LLC ("AM LLC"), 54,428 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,630 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,873 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,908 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 58,081 by AM LLC, 366,727 by BV 2014, 24,458 by BV 2014(B), 12,620 by AM BV2014 and 80,234 by MPM OIF.
F6The shares were sold as follows: 3,171 by AM LLC, 20,020 by BV 2014, 1,335 by BV 2014(B), 689 by AM BV2014 and 4,380 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4304 to $0.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 54,910 by AM LLC, 346,707 by BV 2014, 23,123 by BV 2014(B), 11,931 by AM BV2014 and 75,854 by MPM OIF.
F9The shares were sold as follows: 3,187 by AM LLC, 20,124 by BV 2014, 1,342 by BV 2014(B), 693 by AM BV2014 and 4,403 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.44 to $0.4557 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 66,701 by AM LLC, 421,155 by BV 2014, 28,088 by BV 2014(B), 14,493 by AM BV2014 and 92,142 by MPM OIF.
F2The shares were sold as follows: 8,663 by MPM Asset Management LLC ("AM LLC"), 54,692 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,648 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,883 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,966 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.46 to $0.49705 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 73,157 by AM LLC, 461,914 by BV 2014, 30,807 by BV 2014(B), 15,896 by AM BV2014 and 101,059 by MPM OIF.
F6The shares were sold as follows: 2,968 by AM LLC, 18,736 by BV 2014, 1,250 by BV 2014(B), 645 by AM BV2014 and 4,099 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.455 to $0.4858 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 70,189 by AM LLC, 443,178 by BV 2014, 29,557 by BV 2014(B), 15,251 by AM BV2014 and 96,960 by MPM OIF.
F9The shares were sold as follows: 3,488 by AM LLC, 22,023 by BV 2014, 1,469 by BV 2014(B), 758 by AM BV2014 and 4,818 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4436 to $0.4826 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 81,820 by AM LLC, 516,606 by BV 2014, 34,455 by BV 2014(B), 17,779 by AM BV2014 and 113,025 by MPM OIF.
F2The shares were sold as follows: 3,899 by MPM Asset Management LLC ("AM LLC"), 24,614 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,642 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 847 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,385 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4126 to $0.4426 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 98,467 by AM LLC, 621,710 by BV 2014, 41,465 by BV 2014(B), 21,397 by AM BV2014 and 136,021 by MPM OIF.
F6The shares were sold as follows: 9,367 by AM LLC, 59,139 by BV 2014, 3,944 by BV 2014(B), 2,036 by AM BV2014 and 12,939 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.42 to $0.4614 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 89,100 by AM LLC, 562,571 by BV 2014, 37,521 by BV 2014(B), 19,361 by AM BV2014 and 123,082 by MPM OIF.
F9The shares were sold as follows: 7,280 by AM LLC, 45,965 by BV 2014, 3,066 by BV 2014(B), 1,582 by AM BV2014 and 10,057 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.40905 to $0.4455 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 102,366 by AM LLC, 646,324 by BV 2014, 43,107 by BV 2014(B), 22,244 by AM BV2014 and 141,406 by MPM OIF.
F2The shares were sold as follows: 2,377 by MPM Asset Management LLC ("AM LLC"), 15,006 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,001 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 517 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,283 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4931 to $0.5059 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 118,316 by AM LLC, 747,025 by BV 2014, 49,823 by BV 2014(B), 25,710 by AM BV2014 and 163,438 by MPM OIF.
F6The shares were sold as follows: 6,747 by AM LLC, 42,596 by BV 2014, 2,841 by BV 2014(B), 1,466 by AM BV2014 and 9,320 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4243 to $0.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 111,569 by AM LLC, 704,429 by BV 2014, 46,982 by BV 2014(B), 24,244 by AM BV2014 and 154,118 by MPM OIF.
F9The shares were sold as follows: 9,203 by AM LLC, 58,105 by BV 2014, 3,875 by BV 2014(B), 2,000 by AM BV2014 and 12,712 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F2The shares were sold as follows: 4,787 by MPM Asset Management LLC ("AM LLC"), 30,223 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,016 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,040 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,613 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5077 to $0.61 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 120,693 by AM LLC, 762,031 by BV 2014, 50,824 by BV 2014(B), 26,227 by AM BV2014 and 166,721 by MPM OIF.
F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.76 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
F4Held directly by Nexus Fund II.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.71 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6286 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 125,480 by AM LLC, 792,254 by BV 2014, 52,840 by BV 2014(B), 27,267 by AM BV2014 and 173,334 by MPM OIF.
F2The shares were sold as follows: 32,757 by MPM Asset Management LLC ("AM LLC"), 206,820 by MPM BioVentures 2014, L.P. ("BV 2014"), 13,795 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 7,119 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 45,250 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6183 to $0.7668 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 136,390 by AM LLC, 861,140 by BV 2014, 57,435 by BV 2014(B), 29,638 by AM BV2014 and 188,405 by MPM OIF.
F6The shares were sold as follows: 3,637 by AM LLC, 22,965 by BV 2014, 1,532 by BV 2014(B), 790 by AM BV2014 and 5,024 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.7002 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 132,753 by AM LLC, 838,175 by BV 2014, 55,903 by BV 2014(B), 28,848 by AM BV2014 and 183,381 by MPM OIF.
F9The shares were sold as follows: 7,273 by AM LLC, 45,921 by BV 2014, 3,063 by BV 2014(B), 1,581 by AM BV2014 and 10,047 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.667 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 169,147 by AM LLC, 1,067,960 by BV 2014, 71,230 by BV 2014(B), 36,757 by AM BV2014 and 233,655 by MPM OIF.
F2The shares were sold as follows: 735 by MPM Asset Management LLC ("AM LLC"), 4,640 by MPM BioVentures 2014, L.P. ("BV 2014"), 310 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 160 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,015 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6616 to $0.7253 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 179,188 by AM LLC, 1,131,359 by BV 2014, 75,458 by BV 2014(B), 38,939 by AM BV2014 and 247,526 by MPM OIF.
F6The shares were sold as follows: 1,568 by AM LLC, 9,900 by BV 2014, 660 by BV 2014(B), 341 by AM BV2014 and 2,166 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.7054 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 177,620 by AM LLC, 1,121,459 by BV 2014, 74,798 by BV 2014(B), 38,598 by AM BV2014 and 245,360 by MPM OIF.
F9The shares were sold as follows: 8,473 by AM LLC, 53,499 by BV 2014, 3,568 by BV 2014(B), 1,841 by AM BV2014 and 11,705 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.7497 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 179,923 by AM LLC, 1,135,999 by BV 2014, 75,768 by BV 2014(B), 39,099 by AM BV2014 and 248,541 by MPM OIF.
F2The shares were sold as follows: 18,028 by MPM Asset Management LLC ("AM LLC"), 113,821 by MPM BioVentures 2014, L.P. ("BV 2014"), 7,592 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 3,918 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 24,903 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.688 to $0.7458 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 191,318 by AM LLC, 1,207,945 by BV 2014, 80,567 by BV 2014(B), 41,576 by AM BV2014 and 264,281 by MPM OIF.
F6The shares were sold as follows: 6,256 by AM LLC, 39,501 by BV 2014, 2,635 by BV 2014(B), 1,360 by AM BV2014 and 8,642 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7011 to $0.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 185,062 by AM LLC, 1,168,444 by BV 2014, 77,932 by BV 2014(B), 40,216 by AM BV2014 and 255,639 by MPM OIF.
F9The shares were sold as follows: 5,139 by AM LLC, 32,445 by BV 2014, 2,164 by BV 2014(B), 1,117 by AM BV2014 and 7,098 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.68 to $0.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 209,346 by AM LLC, 1,321,766 by BV 2014, 88,159 by BV 2014(B), 45,494 by AM BV2014 and 289,184 by MPM OIF.
F2The shares were sold as follows: 5,779 by MPM Asset Management LLC ("AM LLC"), 36,488 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,434 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,256 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 7,983 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.818 to $0.8788 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 225,629 by AM LLC, 1,424,566 by BV 2014, 95,016 by BV 2014(B), 49,033 by AM BV2014 and 311,676 by MPM OIF.
F6The shares were sold as follows: 10,223 by AM LLC, 64,541 by BV 2014, 4,305 by BV 2014(B), 2,222 by AM BV2014 and 14,121 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.673 to $0.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 215,406 by AM LLC, 1,360,025 by BV 2014, 90,711 by BV 2014(B), 46,811 by AM BV2014 and 297,555 by MPM OIF.
F9The shares were sold as follows: 6,060 by AM LLC, 38,259 by BV 2014, 2,552 by BV 2014(B), 1,317 by AM BV2014 and 8,371 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F2The shares were sold as follows: 4,152 by MPM Asset Management LLC ("AM LLC"), 26,213 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,749 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 893 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,775 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.535 to $0.5495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 231,408 by AM LLC, 1,461,054 by BV 2014, 97,450 by BV 2014(B), 50,289 by AM BV2014 and 319,659 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5305 to $0.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 235,560 by AM LLC, 1,487,267 by BV 2014, 99,199 by BV 2014(B), 51,182 by AM BV2014 and 325,434 by MPM OIF.
F2The shares were sold as follows: 4,621 by MPM Asset Management LLC ("AM LLC"), 29,195 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,947 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,006 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,429 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.53675 to $0.5697 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 242,837 by AM LLC, 1,533,244 by BV 2014, 102,265 by BV 2014(B), 52,766 by AM BV2014 and 335,559 by MPM OIF.
F6The shares were sold as follows: 3,275 by AM LLC, 20,692 by BV 2014, 1,380 by BV 2014(B), 712 by AM BV2014 and 4,557 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5524 to $0.5857 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 239,562 by AM LLC, 1,512,552 by BV 2014, 100,885 by BV 2014(B), 52,054 by AM BV2014 and 331,002 by MPM OIF.
F9The shares were sold as follows: 4,002 by AM LLC, 25,285 by BV 2014, 1,686 by BV 2014(B), 872 by AM BV2014 and 5,568 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5608 to $0.606 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 247,458 by AM LLC, 1,562,439 by BV 2014, 104,212 by BV 2014(B), 53,772 by AM BV2014 and 341,988 by MPM OIF.
F2The shares were sold as follows: 825 by MPM Asset Management LLC ("AM LLC"), 5,215 by MPM BioVentures 2014, L.P. ("BV 2014"), 348 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 180 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,148 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6243 to $0.6368 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 256,407 by AM LLC, 1,618,978 by BV 2014, 107,983 by BV 2014(B), 55,720 by AM BV2014 and 354,439 by MPM OIF.
F6The shares were sold as follows: 2,640 by AM LLC, 16,678 by BV 2014, 1,112 by BV 2014(B), 575 by AM BV2014 and 3,673 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6019 to $0.6583 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 253,767 by AM LLC, 1,602,300 by BV 2014, 106,871 by BV 2014(B), 55,145 by AM BV2014 and 350,766 by MPM OIF.
F9The shares were sold as follows: 6,309 by AM LLC, 39,861 by BV 2014, 2,659 by BV 2014(B), 1,373 by AM BV2014 and 8,778 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6276 to $0.6598 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 257,232 by AM LLC, 1,624,193 by BV 2014, 108,331 by BV 2014(B), 55,900 by AM BV2014 and 355,587 by MPM OIF.
F2The shares were sold as follows: 1,966 by MPM Asset Management LLC ("AM LLC"), 12,420 by MPM BioVentures 2014, L.P. ("BV 2014"), 828 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 429 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,735 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.63435 to $0.6549 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 262,868 by AM LLC, 1,659,794 by BV 2014, 110,705 by BV 2014(B), 57,125 by AM BV2014 and 363,427 by MPM OIF.
F6The shares were sold as follows: 4,361 by AM LLC, 27,548 by BV 2014, 1,837 by BV 2014(B), 948 by AM BV2014 and 6,067 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.6599 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 258,507 by AM LLC, 1,632,246 by BV 2014, 108,868 by BV 2014(B), 56,177 by AM BV2014 and 357,360 by MPM OIF.
F9The shares were sold as follows: 1,275 by AM LLC, 8,053 by BV 2014, 537 by BV 2014(B), 277 by AM BV2014 and 1,773 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.6499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 264,834 by AM LLC, 1,672,214 by BV 2014, 111,533 by BV 2014(B), 57,554 by AM BV2014 and 366,162 by MPM OIF.
F2The shares were sold as follows: 3,728 by MPM Asset Management LLC ("AM LLC"), 23,551 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,571 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 811 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,186 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6085 to $0.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 269,490 by AM LLC, 1,701,633 by BV 2014, 113,495 by BV 2014(B), 58,568 by AM BV2014 and 372,641 by MPM OIF.
F6The shares were sold as follows: 2,670 by AM LLC, 16,870 by BV 2014, 1,125 by BV 2014(B), 582 by AM BV2014 and 3,715 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6038 to $0.6359 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 266,820 by AM LLC, 1,684,763 by BV 2014, 112,370 by BV 2014(B), 57,986 by AM BV2014 and 368,926 by MPM OIF.
F9The shares were sold as follows: 1,986 by AM LLC, 12,549 by BV 2014, 837 by BV 2014(B), 432 by AM BV2014 and 2,764 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6337 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 288,648 by AM LLC, 1,822,667 by BV 2014, 121,568 by BV 2014(B), 62,734 by AM BV2014 and 399,295 by MPM OIF.
F12The shares were sold as follows: 3,812 by AM LLC, 24,082 by BV 2014, 1,606 by BV 2014(B), 829 by AM BV2014 and 5,303 by MPM OIF.
F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6165 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F14The shares are held as follows: 284,836 by AM LLC, 1,798,585 by BV 2014, 119,962 by BV 2014(B), 61,905 by AM BV2014 and 393,992 by MPM OIF.
F15The shares were sold as follows: 11,618 by AM LLC, 73,401 by BV 2014, 4,896 by BV 2014(B), 2,526 by AM BV2014 and 16,165 by MPM OIF.
F16The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.58955 to $0.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F17The shares are held as follows: 273,218 by AM LLC, 1,725,184 by BV 2014, 115,066 by BV 2014(B), 59,379 by AM BV2014 and 377,827 by MPM OIF.
F2The shares were sold as follows: 6,344 by MPM Asset Management LLC ("AM LLC"), 40,082 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,673 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,381 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,827 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6596 to $0.7341 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 298,034 by AM LLC, 1,881,964 by BV 2014, 125,523 by BV 2014(B), 64,775 by AM BV2014 and 412,354 by MPM OIF.
F6The shares were sold as follows: 7,641 by AM LLC, 48,274 by BV 2014, 3,220 by BV 2014(B), 1,662 by AM BV2014 and 10,631 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.61 to $0.6728 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 290,393 by AM LLC, 1,833,690 by BV 2014, 122,303 by BV 2014(B), 63,113 by AM BV2014 and 401,723 by MPM OIF.
F9The shares were sold as follows: 1,745 by AM LLC, 11,023 by BV 2014, 735 by BV 2014(B), 379 by AM BV2014 and 2,428 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.095 to $1.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 304,378 by AM LLC, 1,922,046 by BV 2014, 128,196 by BV 2014(B), 66,156 by AM BV2014 and 421,181 by MPM OIF.
F2The shares were sold as follows: 2,529 by MPM Asset Management LLC ("AM LLC"), 15,977 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,066 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 550 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,518 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 307,002 by AM LLC, 1,938,625 by BV 2014, 129,302 by BV 2014(B), 66,727 by AM BV2014 and 424,832 by MPM OIF.
F6The shares were sold as follows: 1,556 by AM LLC, 9,832 by BV 2014, 656 by BV 2014(B), 339 by AM BV2014 and 2,165 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 305,446 by AM LLC, 1,928,793 by BV 2014, 128,646 by BV 2014(B), 66,388 by AM BV2014 and 422,667 by MPM OIF.
F9The shares were sold as follows: 1,068 by AM LLC, 6,747 by BV 2014, 450 by BV 2014(B), 232 by AM BV2014 and 1,486 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.06 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 309,531 by AM LLC, 1,954,602 by BV 2014, 130,368 by BV 2014(B),67,277 by AM BV2014 and 428,350 by MPM OIF.
F2The shares were sold as follows: 3,969 by MPM Asset Management LLC ("AM LLC"), 25,077 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,673 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 863 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,522 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9742 to $1.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 314,437 by AM LLC, 1,985,601 by BV 2014, 132,436 by BV 2014(B), 68,344 by AM BV2014 and 435,177 by MPM OIF.
F6The shares were sold as follows: 2,996 by AM LLC, 18,930 by BV 2014, 1,263 by BV 2014(B), 651 by AM BV2014 and 4,169 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 311,441 by AM LLC, 1,966,671 by BV 2014, 131,173 by BV 2014(B), 67,693 by AM BV2014 and 431,008 by MPM OIF.
F9The shares were sold as follows: 1,910 by AM LLC, 12,069 by BV 2014, 805 by BV 2014(B), 416 by AM BV2014 and 2,658 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.99 to $1.025 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 318,406 by AM LLC, 2,010,678 by BV 2014, 134,109 by BV 2014(B), 69,207 by AM BV2014 and 440,699 by MPM OIF.
F2The shares were sold as follows: 1,772 by MPM Asset Management LLC ("AM LLC"), 11,197 by MPM BioVentures 2014, L.P. ("BV 2014"), 747 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 386 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,466 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9434 to $0.9863 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 326,816 by AM LLC, 2,063,807 by BV 2014, 137,652 by BV 2014(B), 71,035 by AM BV2014 and 452,400 by MPM OIF.
F6The shares were sold as follows: 3,642 by AM LLC, 23,006 by BV 2014, 1,534 by BV 2014(B), 792 by AM BV2014 and 5,067 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9582 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 323,174 by AM LLC, 2,040,801 by BV 2014, 136,118 by BV 2014(B), 70,243 by AM BV2014 and 447,333 by MPM OIF.
F9The shares were sold as follows: 4,768 by AM LLC, 30,123 by BV 2014, 2,009 by BV 2014(B), 1,036 by AM BV2014 and 6,634 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.
F2The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.
F6The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.
F9The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.
F2The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.
F6The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.
F9The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014 and 454,866 by MPM OIF.
F2The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014 and 468,282 by MPM OIF.
F6The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014 and 5,466 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014 and 462,816 by MPM OIF.
F9The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014 and 7,950 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology.
F2The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,755 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology
F6The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology
F9The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology.
F2The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,755 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology.
F6The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology.
F9The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014 and 473,944 by MPM OIF.
F2The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014 and 481,700 by MPM OIF.
F6The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014 and 1,937 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014 and 479,763 by MPM OIF.
F9The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014 and 5,819 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology.
F2The shares were sold as follows: 4,417 by MPM Asset Management LLC ("AM LLC"), 27,904 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,861 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 960 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,145 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 23,044 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014, 500,047 by MPM OIF and 1,885,265 by UBS Oncology.
F6The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014, 8,483 by MPM OIF and 31,810 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014, 491,564 by MPM OIF and 1,853,455 by UBS Oncology.
F9The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology.
F2The shares were sold as follows: 4,417 by MPM Asset Management LLC ("AM LLC"), 27,904 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,861 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 960 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,145 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 23,044 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014, 500,047 by MPM OIF and 1,885,265 by UBS Oncology.
F6The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014, 8,483 by MPM OIF and 31,810 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014, 491,564 by MPM OIF and 1,853,455 by UBS Oncology.
F9The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014 and 487,501 by MPM OIF.
F2The shares were sold as follows: 4,417 by MPM Asset Management LLC ("AM LLC"), 27,904 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,861 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 960 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,145 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014 and 500,047 by MPM OIF.
F6The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014 and 8,483 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014 and 491,564 by MPM OIF.
F9The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014 and 4,063 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology.
F2The shares were sold as follows: 3,613 by MPM Asset Management LLC ("AM LLC"), 22,827 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,523 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 786 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,027 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 18,851 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology.
F6The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology.
F9The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology.
F2The shares were sold as follows: 3,613 by MPM Asset Management LLC ("AM LLC"), 22,827 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,523 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 786 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,027 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 18,851 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology.
F6The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology.
F9The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014 and 506,192 by MPM OIF.
F2The shares were sold as follows: 3,613 by MPM Asset Management LLC ("AM LLC"), 22,827 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,523 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 786 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,027 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014 and 516,458 by MPM OIF.
F6The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014 and 6,335 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014 and 510,123 by MPM OIF.
F9The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014 and 3,931 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014, 521,485 by MPM OIF and 1,965,659 by UBS Oncology.
F2The shares were sold as follows: 6,244 by MPM Asset Management LLC ("AM LLC"), 39,450 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,631 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,688 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 32,579 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014, 532,824 by MPM OIF and 2,008,179 by UBS Oncology.
F6The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014, 5,888 by MPM OIF and 22,080 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014, 526,936 by MPM OIF and 1,986,099 by UBS Oncology.
F9The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014, 5,451 by MPM OIF and 20,440 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014, 521,485 by MPM OIF and 1,965,659 by UBS Oncology.
F2The shares were sold as follows: 6,244 by MPM Asset Management LLC ("AM LLC"), 39,450 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,631 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,688 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 32,579 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014, 532,824 by MPM OIF and 2,008,179 by UBS Oncology.
F6The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014, 5,888 by MPM OIF and 22,080 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014, 526,936 by MPM OIF and 1,986,099 by UBS Oncology.
F9The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014, 5,451 by MPM OIF and 20,440 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014 and 521,485 by MPM OIF.
F2The shares were sold as follows: 6,244 by MPM Asset Management LLC ("AM LLC"), 39,450 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,631 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,688 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014 and 532,824 by MPM OIF.
F6The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014 and 5,888 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014 and 526,936 by MPM OIF.
F9The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014 and 5,451 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014, 545,397 by MPM OIF and 2,055,326 by UBS Oncology.
F12The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014, 3,885 by MPM OIF and 14,568 by UBS Oncology.
F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F14The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014, 541,512 by MPM OIF and 2,040,758 by UBS Oncology.
F2The shares were sold as follows: 4,702 by MPM Asset Management LLC ("AM LLC"), 29,704 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,981 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,022 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,541 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 24,530 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology.
F6The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014, 4,640 by MPM OIF and 17,398 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014, 550,728 by MPM OIF and 2,075,318 by UBS Oncology.
F9The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014, 5,331 by MPM OIF and 19,992 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014, 545,397 by MPM OIF and 2,055,326 by UBS Oncology.
F12The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014, 3,885 by MPM OIF and 14,568 by UBS Oncology.
F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F14The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014, 541,512 by MPM OIF and 2,040,758 by UBS Oncology.
F2The shares were sold as follows: 4,702 by MPM Asset Management LLC ("AM LLC"), 29,704 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,981 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,022 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,541 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 24,530 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F5The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology.
F6The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014, 4,640 by MPM OIF and 17,398 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014, 550,728 by MPM OIF and 2,075,318 by UBS Oncology.
F9The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014, 5,331 by MPM OIF and 19,992 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014 and 545,397 by MPM OIF.
F12The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014 and 3,885 by MPM OIF.
F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F14The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014 and 541,512 by MPM OIF.
F2The shares were sold as follows: 4,702 by MPM Asset Management LLC ("AM LLC"), 29,704 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,981 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,022 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,541 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014 and 555,368 by MPM OIF.
F6The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014 and 4,640 by MPM OIF.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014 and 550,728 by MPM OIF.
F9The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014 and 5,331 by MPM OIF.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014, 561,909 by MPM OIF and 2,117,246 by UBS Oncology.
F2. The shares were sold as follows: 9,645 by MPM Asset Management LLC ("AM LLC"), 60,937 by MPM BioVentures 2014, L.P. ("BV 2014"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,420 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 50,324 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F3MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014, 571,690 by MPM OIF and 2,153,927 by UBS Oncology.
F6The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014, 4,580 by MPM OIF and 17,176 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014, 567,110 by MPM OIF and 2,136,751 by UBS Oncology.
F9The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014, 5,201 by MPM OIF and 19,505 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014, 561,909 by MPM OIF and 2,117,246 by UBS Oncology.
F2The shares were sold as follows: 9,645 by MPM Asset Management LLC ("AM LLC"), 60,937 by MPM BioVentures 2014, L.P. ("BV 2014"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,420 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 50,324 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F3MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014, 571,690 by MPM OIF and 2,153,927 by UBS Oncology.
F6The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014, 4,580 by MPM OIF and 17,176 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014, 567,110 by MPM OIF and 2,136,751 by UBS Oncology.
F9The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014, 5,201 by MPM OIF and 19,505 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014 and 561,909 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F2The shares were sold as follows: 9,645 by MPM Asset Management LLC ("AM LLC"), 60,937 by MPM BioVentures 2014, L.P. ("BV 2014"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 13,420 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014 and 571,690 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014 and 4,580 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014 and 567,110 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F8The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014 and 5,201 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014, 585,110 by MPM OIF and 2,204,251 by UBS Oncology.
F2The shares were sold as follows: 5,969 by MPM Asset Management LLC ("AM LLC"), 37,709 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,304 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 31,141 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F3MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology.
F6The shares were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014, 10,894 by MPM OIF and 40,852 by UBS Oncology.
F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014, 594,095 by MPM OIF and 2,237,945 by UBS Oncology.
F9The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014, 8,985 by MPM OIF and 33,694 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014, 585,110 by MPM OIF and 2,204,251 by UBS Oncology.
F2The shares were sold as follows: 5,969 by MPM Asset Management LLC ("AM LLC"), 37,709 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,304 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 31,141 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F3MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology.
F6The shares were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014, 10,894 by MPM OIF and 40,852 by UBS Oncology.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014, 594,095 by MPM OIF and 2,237,945 by UBS Oncology.
F9The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014, 8,985 by MPM OIF and 33,694 by UBS Oncology.
F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F10. The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014 and 585,110 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F2The shares were sold as follows: 5,969 by MPM Asset Management LLC ("AM LLC"), 37,709 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,304 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014 and 604,989 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5The were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014 and 10,894 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014 and 594,095 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F8The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014 and 8,985 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
